Your browser doesn't support javascript.
loading
Benefits of early treatment with natalizumab: a real-world study.
Ontaneda, Daniel; Mowry, Ellen M; Newsome, Scott D; Naismith, Robert T; Nicholas, Jacqueline; Fisher, Elizabeth; de Moor, Carl; Bohn, Justin; Ho, Pei-Ran; Sandrock, Al; Rudick, Richard; Williams, James R.
Afiliación
  • Ontaneda D; Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, USA.
  • Mowry EM; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Newsome SD; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Naismith RT; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
  • Nicholas J; OhioHealth MS Center, Columbus, OH, USA.
  • Fisher E; Digital Health, Biogen, 225 Binney Street, Cambridge, MA, USA.
  • de Moor C; Digital Health, Biogen, 225 Binney Street, Cambridge, MA, USA.
  • Bohn J; Digital Health, Biogen, 225 Binney Street, Cambridge, MA, USA.
  • Ho PR; Global Medical, Biogen, 225 Binney Street, Cambridge, MA, USA, at the time of this study.
  • Sandrock A; Research & Development, Biogen, 225 Binney Street, Cambridge, MA, USA.
  • Rudick R; Developmental Sciences, Biogen, 225 Binney Street, Cambridge, MA, USA, at the time of this study.
  • Williams JR; Digital Health, Biogen, 225 Binney Street, Cambridge, MA, USA. Electronic address: james.williams@biogen.com.
Mult Scler Relat Disord ; 68: 104216, 2022 Dec.
Article en En | MEDLINE | ID: mdl-36288658
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article